[go: up one dir, main page]

MX2018005100A - Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos. - Google Patents

Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos.

Info

Publication number
MX2018005100A
MX2018005100A MX2018005100A MX2018005100A MX2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A MX 2018005100 A MX2018005100 A MX 2018005100A
Authority
MX
Mexico
Prior art keywords
disorders
treatment
azepine compounds
otic diseases
dibenzo azepine
Prior art date
Application number
MX2018005100A
Other languages
English (en)
Other versions
MX378973B (es
Inventor
Jon Seiders Thomas
Yuling Lee Catherine
Li Yiwei
Original Assignee
Inception 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inception 3 Inc filed Critical Inception 3 Inc
Publication of MX2018005100A publication Critical patent/MX2018005100A/es
Publication of MX378973B publication Critical patent/MX378973B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona el Compuesto I cristalino y el Compuesto II cristalino, composiciones farmacéuticas que comprenden uno los compuestos cristalinos adecuados para la administración intratimpánica, y métodos para tratar trastornos óticos utilizando los compuestos cristalinos y las composiciones farmacéuticas.
MX2018005100A 2015-10-30 2016-10-27 Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos óticos. MX378973B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248625P 2015-10-30 2015-10-30
PCT/US2016/059194 WO2017075264A1 (en) 2015-10-30 2016-10-27 Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders

Publications (2)

Publication Number Publication Date
MX2018005100A true MX2018005100A (es) 2019-05-16
MX378973B MX378973B (es) 2025-03-10

Family

ID=57241193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005100A MX378973B (es) 2015-10-30 2016-10-27 Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos óticos.

Country Status (15)

Country Link
US (2) US10301266B2 (es)
EP (1) EP3368515B1 (es)
JP (1) JP6535822B2 (es)
KR (1) KR102130458B1 (es)
CN (1) CN109071450B (es)
AU (1) AU2016344138B2 (es)
CA (1) CA3002874C (es)
ES (1) ES2751082T3 (es)
IL (1) IL258660B (es)
MX (1) MX378973B (es)
NZ (1) NZ741553A (es)
PH (1) PH12018500886A1 (es)
RU (1) RU2707284C1 (es)
WO (1) WO2017075264A1 (es)
ZA (1) ZA201802576B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368515B1 (en) * 2015-10-30 2019-07-17 Inception 3, Inc. Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
AU2019299217B2 (en) 2018-07-03 2025-04-03 Fennec Pharmaceuticals, Inc. Formulations of anhydrous sodium thiosulfate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
KR20070087233A (ko) * 2003-09-09 2007-08-27 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
HRP20151197T1 (hr) * 2003-10-06 2015-12-04 F. Hoffmann - La Roche Ag Supstituirani derivati dibenzo-azepina i benzo-diazepina, koji su korisni kao inhibitori gama-sekretaze
JP2010517954A (ja) * 2007-02-02 2010-05-27 エフ．ホフマン−ラ ロシュ アーゲー ６−オキソ−６，７−ジヒドロ−５Ｈ−ジベンゾ［ｂ，ｄ］アゼピン−７−イル誘導体
US7579464B2 (en) * 2007-05-25 2009-08-25 Hoffmann-La Roche Inc. Process for preparation of enantiomerically pure compounds
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
EP2490722A4 (en) 2009-10-21 2014-03-05 Otonomy Inc MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS
HK1211875A1 (en) * 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP3368515B1 (en) * 2015-10-30 2019-07-17 Inception 3, Inc. Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
JP6904612B2 (ja) * 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法

Also Published As

Publication number Publication date
JP6535822B2 (ja) 2019-06-26
CA3002874C (en) 2020-05-05
KR20180070694A (ko) 2018-06-26
MX378973B (es) 2025-03-10
NZ750653A (en) 2021-03-26
RU2707284C1 (ru) 2019-11-26
CA3002874A1 (en) 2017-05-04
AU2016344138A1 (en) 2018-05-10
CN109071450A (zh) 2018-12-21
US10865188B2 (en) 2020-12-15
ZA201802576B (en) 2019-07-31
US20190194140A1 (en) 2019-06-27
EP3368515B1 (en) 2019-07-17
EP3368515A1 (en) 2018-09-05
US20180273483A1 (en) 2018-09-27
JP2018532798A (ja) 2018-11-08
WO2017075264A1 (en) 2017-05-04
ES2751082T3 (es) 2020-03-30
CN109071450B (zh) 2021-06-22
IL258660A (en) 2018-06-28
AU2016344138B2 (en) 2019-06-06
KR102130458B1 (ko) 2020-07-08
PH12018500886A1 (en) 2018-10-29
IL258660B (en) 2021-02-28
US10301266B2 (en) 2019-05-28
WO2017075264A8 (en) 2018-05-24
NZ741553A (en) 2019-08-30

Similar Documents

Publication Publication Date Title
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20150571A (es) Compuestos y composiciones terapéuticos
MX2021009673A (es) Moduladores de ror-gamma.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
NI201600071A (es) Compuestos de inhibidor de autotaxina
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2018005100A (es) Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos.